一项针对转移性去势抵抗性前列腺癌参与者测试伊那沃利西布治疗的研究 (InavoPC)
一项评估伊纳沃利西联合恩杂鲁胺对比医生选择ARPI或多西他赛治疗转移性去势抵抗性前列腺癌患者的疗效和安全性的II期、随机、多中心、开放标签研究
This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
研究联系人备份
- 姓名:Reference Study ID Number: CO45813 https://forpatients.roche.com/ No attachments to email below.
- 电话号码:888-662-6728 (U.S. and Canada)
- 邮箱:global-roche-genentech-trials@gene.com
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- 招聘中
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1E2
- 招聘中
- Jewish General Hospital
-
Montreal、Quebec、加拿大、H2X 0A9
- 招聘中
- Centre de recherche du Centre Hospitalier de l'Universite de Montreal
-
-
-
-
-
Ankara、土耳其(türkiye)、6590
- 招聘中
- Ankara Universitesi Tip Fakultesi Hastaneleri - Cebeci Hastanesi
-
Atakum、土耳其(türkiye)、55200
- 招聘中
- VM Medical Park Samsun Hastanesi
-
Istanbul、土耳其(türkiye)、41380
- 招聘中
- Koc Universitesi Hastanesi
-
Izmir、土耳其(türkiye)、35101
- 招聘中
- Izmir Medical Point Hospital
-
Seyhan、土耳其(türkiye)、1140
- 招聘中
- Medical Park Seyhan Hospital
-
-
-
-
Guanajuato
-
León、Guanajuato、墨西哥、37530
- 招聘中
- Hospital MAC León
-
-
Mexico CITY (federal District)
-
Benito Juárez、Mexico CITY (federal District)、墨西哥、3240
- 招聘中
- Productos y Servicios Oncologicos Acacias SA de CV
-
Mexico City、Mexico CITY (federal District)、墨西哥、3100
- 招聘中
- Health Pharma Professional Research S.A de C.V.
-
-
-
-
-
Rio de Janeiro、巴西、20230-130
- 招聘中
- Instituto Nacional de Cancer - INCa
-
São Paulo、巴西、01246-000
- 招聘中
- Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira - ICESP
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90035-074
- 招聘中
- Irmandade Da Santa Casa de Misericordia de Porto Alegre
-
-
São Paulo
-
Santo André、São Paulo、巴西、09060-650
- 招聘中
- CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
-
São José do Rio Preto、São Paulo、巴西、15090-000
- 招聘中
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
-
-
-
-
-
Hamburg、德国、20246
- 招聘中
- Universitätsklinikum Hamburg-Eppendorf
-
Münster、德国、48149
- 招聘中
- Universitätsklinikum Münster
-
Nürtingen、德国、72622
- 招聘中
- Studienpraxis Urologie
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau、Baden-Wurttemberg、德国、79106
- 招聘中
- Universitätsklinikum Freiburg
-
-
-
-
Lazio
-
Rome、Lazio、意大利、00144
- 招聘中
- Istituti Fisioterapici Ospitalieri
-
-
Lombardy
-
Milan、Lombardy、意大利、20133
- 招聘中
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan、Lombardy、意大利、20132
- 招聘中
- Ospedale San Raffaele S.r.l. - PPDS
-
-
Veneto
-
Castelfranco Veneto、Veneto、意大利、31033
- 招聘中
- Istituto Oncologico Veneto - Sede di Castelfranco Veneto c/o Ospedale San Giacomo Apostolo
-
-
-
-
-
Lyon、法国、69008
- 招聘中
- Centre Léon Bérard
-
Marseille、法国、13009
- 招聘中
- Institut Paoli Calmettes
-
-
Gironde
-
Bordeaux、Gironde、法国、33000
- 招聘中
- EDOG - Institut Bergonie - PPDS
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、法国、94805
- 招聘中
- Gustave Roussy
-
-
-
-
New South Wales
-
St Leonards、New South Wales、澳大利亚、2065
- 招聘中
- Royal North Shore Hospital-Pacific Hwy
-
-
Queensland
-
Birtinya、Queensland、澳大利亚、4575
- 招聘中
- Sunshine Coast University Hospital
-
Herston、Queensland、澳大利亚、4029
- 招聘中
- Royal Brisbane & Women's Hospital
-
-
Victoria
-
Box Hill、Victoria、澳大利亚、3128
- 招聘中
- Box Hill Hospital
-
-
-
-
California
-
Los Angeles、California、美国、90073-1003
- 招聘中
- VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS
-
San Francisco、California、美国、94115
- 招聘中
- UCSF
-
-
Colorado
-
Aurora、Colorado、美国、80124-5316
- 招聘中
- University of Colorado Cancer Center
-
-
Iowa
-
Iowa City、Iowa、美国、52242-1009
- 招聘中
- Holden Comprehensive Cancer Center
-
-
New York
-
The Bronx、New York、美国、10461
- 招聘中
- Montefiore Einstein Cancer Center
-
-
Rhode Island
-
Providence、Rhode Island、美国、02903-4923
- 招聘中
- Lifespan Cancer Institute
-
-
South Carolina
-
Myrtle Beach、South Carolina、美国、29572
- 招聘中
- Grand Strand Regional Medical Center
-
-
-
-
-
Cardiff、英国、CF14 2TL
- 招聘中
- Velindre Cancer Centre
-
-
Surrey
-
Sutton、Surrey、英国、SM2 5PT
- 招聘中
- The Royal Marsden in Sutton, Surrey - Downs Rd
-
-
-
-
-
Córdoba、西班牙、14004
- 招聘中
- C.H. Regional Reina Sofia - PPDS
-
Madrid、西班牙、28041
- 招聘中
- Hospital Universitario 12 de Octubre
-
Valencia、西班牙、46009
- 招聘中
- Fundacion Instituto Valenciano de Oncologia (IVO)
-
-
Vizcaya
-
Barakaldo、Vizcaya、西班牙、48903
- 招聘中
- Hospital Universitario Cruces
-
-
-
-
-
Seoul、韩国、03080
- 招聘中
- Seoul National University Hospital
-
Seoul、韩国、03722
- 招聘中
- Severance Hospital, Yonsei University Health System
-
Seoul、韩国、06351
- 招聘中
- Samsung Medical Center
-
Seoul、韩国、05505
- 招聘中
- Asan Medical Center.
-
-
Gyeonggido
-
Seongnam-si、Gyeonggido、韩国、13620
- 招聘中
- Seoul National University Bundang Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the prostate without small-cell or neuroendocrine features
- Progressive metastatic CRPC, defined as any of the following: PSA progression, defined by a minimum of two rising PSA values from three consecutive assessments with an interval of at least 7 days between assessments and with a minimal starting value of PSA >=1 ng/mL; The most recent qualifying PSA value must be determined within 14 days of enrollment; Soft tissue disease progression, defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1); Bone disease progression, defined by PCWG3 criteria, with two or more new metastatic bone lesions on a whole-body radionuclide bone scan
- Treatment with at least one, but no more than one, prior second-generation ARPi (abiraterone, apalutamide, enzalutamide, darolutamide) for at least 12 weeks for HSPC or CRPC
- Availability of a tumor tissue specimen that is suitable (e.g., adequate quality and quantity) for use in determining biomarker status
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Fasting glucose <126 mg/dL and HbA1c < 6%
Exclusion Criteria:
- Presence of liver metastasis
- Prior treatment with any phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT), or mammalian target of rapamycin (mTOR) inhibitor, or with any agent with a mechanism of action of inhibiting the PI3K/AKT/mTOR pathway
- Type 1 or Type 2 diabetes mellitus
- Prior treatment for mCRPC with cytotoxic chemotherapy or novel hormonal treatments (e.g., androgen receptor degraders, CYP11 inhibitors), with the following treatments permitted: Prior docetaxel in mHSPC, providing no evidence of disease progression occurred during treatment or within 6 months of treatment completion; Prior docetaxel in the adjuvant or neoadjuvant setting providing no evidence of disease progression occurred during treatment or within 12 months of treatment completion; Prior treatment with sipuleucel-T, with the last dose administered >28 days prior to start of treatment; Prior PARPi therapy, as per local prescribing information, with the last dose administered >14 days prior to start of treatment; One prior RLT or radiotherapeutic agent (e.g., PSMA-targeted RLT, Radium 223) with the last dose administered >8 weeks prior to start of treatment
- Other concurrent anti-cancer therapy except for androgen deprivation therapy
- Treatment with strong CYP2C8 inhibitors, strong or moderate CYP2C8 inducers, or strong CYP3A4 inducers within 1 week or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment
- Transfusion of any blood product for the sole purpose of making a potential participant eligible for study inclusion or within 28 days of enrollment
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1
Participants will receive Inavolisib plus enzalutamide |
Inavolisib will be administered orally as per the schedule specified in the protocol. Enzalutamide will be administered orally as per the schedule specified in the protocol. |
|
有源比较器:Arm 2
Participants will receive either ARPi switch (enzalutamide or abiraterone) or docetaxel |
Enzalutamide will be administered orally as per the schedule specified in the protocol. Abiraterone will be administered orally as per the schedule specified in the protocol. Docetaxel will be administered intravenously as per the schedule specified in the protocol. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
影像学无进展生存期 (rPFS)
大体时间:最多约5年
|
最多约5年
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
缓解持续时间 (DOR)
大体时间:最长约 5 年
|
最长约 5 年
|
|
总生存期(OS)
大体时间:最长约 5 年
|
最长约 5 年
|
|
确认复合应答率(RR)的参与者百分比
大体时间:最长约5年
|
最长约5年
|
|
达到前列腺特异性抗原90(PSA90)确认标准的受试者比例
大体时间:最长约5年
|
最长约5年
|
|
PSA50(前列腺特异性抗原50)确认参与者的百分比
大体时间:最长约5年
|
最长约5年
|
|
客观缓解率(ORR)
大体时间:最多约5年
|
最多约5年
|
|
发生不良事件(AEs)的参与者百分比
大体时间:最长约5年
|
最长约5年
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CO45813
- 2025-521327-67-00 (克蒂斯)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.